Michele Biscuola

Michele Biscuola

Auto-generated profile, based on publicly available information

Michele Biscuola

Pathology Department Hospital Universitario Virgen del Rocío Sevilla Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
EAEdurne Arriola
Edurne Arriola
RBReyes Bernabé-Caro
Reyes Bernabé-Caro
RCRosario García Campelo
Rosario García Campelo
MBMichele Biscuola
Michele Biscuola
AEAna Belén Enguita
Ana Belén Enguita
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
PURPOSE: The aim of this study was to assess the cost-effectiveness of using next-generation sequencing (NGS) versus single-gene testing (SgT) for the detection of genetic molecular subtypes and oncogenic markers in patients with advanced non–small-cell lung cancer (NSCLC) in the setting of Spanish reference centers. METHODS: A joint model combining decision tree with partitioned survival models was developed. A two-round consensus panel was performed to describe clinical practice of Spanish reference centers, providing data on testing rate, prevalence of alterations, turnaround times, and treatment pathways. Treatment efficacy data and utility values were obtained from the literature. Only direct costs (euros, 2022), obtained from Spanish databases, were included. A lifetime horizon was considered, so a 3% discount rate for future costs and outcomes was considered. Both deterministic and probabilistic sensitivity analyses were performed to assess uncertainty. RESULTS: A target population of 9,734 patients with advanced NSCLC was estimated. If NGS was used instead of SgT, 1,873 more alterations would be detected and 82 more patients could potentially be enrolled in clinical trials. In the long term, using NGS would provide 1,188 additional quality-adjusted life-years (QALYs) in the target population compared with SgT. On the other hand, the incremental cost of NGS versus SgT in the target population was €21,048,580 euros for a lifetime horizon (€1,333,288 for diagnosis phase only). The obtained incremental cost-utility ratios were €25,895 per QALY gained, below the standard cost-effectiveness thresholds. CONCLUSION: Using NGS in Spanish reference centers for the molecular diagnosis of patients with metastatic NSCLC would be a cost-effective strategy over SgT.

3 April 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MDMercedes Delgado-García
Mercedes Delgado-García
BWBirgit Weynand
Birgit Weynand
LGLourdes Gómez-Izquierdo
Lourdes Gómez-Izquierdo
MHMaría José Hernández
María José Hernández
ÁBÁngela María Blanco
Ángela María Blanco
MBMichele Biscuola
Michele Biscuola
Background: Detection of epidermal growth factor receptor (EGFR)mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors inEGFR-mutated patients. Therefore, choosing a suitable technique to testEGFRmutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.The Idylla™EGFRMutation Test is a simple, fast and reliable method designed for the detection ofEGFRmutations from formalin-fixed paraffin-embedded samples.The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System.Methods: EGFRmutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen®EGFRRGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla).Results: The overall agreement between results obtained with the Idylla™EGFRMutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%.Conclusions: The Idylla™EGFRMutation Test passed its clinical validity performance characteristics for accuracy.

25 July 2022 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
BPBelén Pérez-Mies
Belén Pérez-Mies
TCTamara Bd Caniego-Casas
Tamara Bd Caniego-Casas
ICIrene Carretero-Barrio
Irene Carretero-Barrio
MBMichele Biscuola
Michele Biscuola
MGM Ángeles López García
M Ángeles López García
JPJosé Palacios
José Palacios
The relationship between the ductal and lobular components of invasive ductolobular carcinomas (IDLC) has not been fully elucidated. In this study, the molecular alterations of both components were analyzed in a series of 20 IDLC that were selected, not only by morphologic criteria, but also by the loss of E-cadherin expression in the lobular component. We found that 80% of tumors shared alterations of driver genes in both components, being PIK3CA the most common alteration. In addition, 45% of IDLC carried CDH1 mutations in their lobular component that were absent in the ductal component. Fluorescent in situ hybridization analysis of the CDH1 gene excluded homozygous CDH1 loss as a frequent cause of E-cadherin loss in tumors without CDH1 mutations. In addition, no pathogenic mutations of catenin genes were detected in this series of tumors. In 25% of tumors, actionable mutations in PIK3CA, AKT1, and ERBB2 were found in only 1 component. Altogether, our results confirm that most IDLC derive from invasive carcinoma of no special type, in which a population of cells lose E-cadherin and acquire a lobular phenotype. The frequency of CDH1 mutations in IDLC appears to be lower than in conventional invasive lobular carcinomas, suggesting the implication of alternative mechanisms of E-cadherin loss. Moreover, molecular heterogeneity between ductal and lobular areas suggests the need for molecular characterization of both components to guide targeted therapies.

20 August 2019 in Research Square
Verified
Preprint
Open access
MDMercedes Delgado-Garcia
Mercedes Delgado-Garcia
BWBirgit Weynand
Birgit Weynand
LILourdes Gómez Izquierdo
Lourdes Gómez Izquierdo
MBMaría José Hernández Barrera
María José Hernández Barrera
ÁLÁngela María Blanco Lobo
Ángela María Blanco Lobo
MBMichele Biscuola
Michele Biscuola
BackgroundDetection of epidermal growth factor receptor ( EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy tyrosine kinase inhibitors in EGFR -mutated patients. Therefore, choosing a suitable technique for testing EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded sample. The aim of this study was the evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System conducting a Clinical Performance Evaluation.MethodsEGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen ® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla)ResultsThe overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%.ConclusionsThe Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.

28 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
MDMercedes Delgado-Garcia
Mercedes Delgado-Garcia
BWBirgit Weynand
Birgit Weynand
LILourdes Gómez Izquierdo
Lourdes Gómez Izquierdo
MBMaría José Hernández Barrera
María José Hernández Barrera
ÁLÁngela María Blanco Lobo
Ángela María Blanco Lobo
MBMichele Biscuola
Michele Biscuola
Background detection of epidermal growth factor receptor ( EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System. Methods EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen ® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla). Results the overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions the Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.

7 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
MDMercedes Delgado-Garcia
Mercedes Delgado-Garcia
BWBirgit Weynand
Birgit Weynand
LILourdes Gómez Izquierdo
Lourdes Gómez Izquierdo
MBMaría José Hernández Barrera
María José Hernández Barrera
ÁLÁngela María Blanco Lobo
Ángela María Blanco Lobo
MBMichele Biscuola
Michele Biscuola
Background: detection of epidermal growth factor receptor (EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System.Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla).Results: the overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: the Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.